Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients

被引:38
|
作者
Nuytemans, Karen [1 ,2 ,3 ]
Rademakers, Rosa [1 ,2 ,3 ]
Theuns, Jessie [1 ,2 ,3 ]
Pals, Philippe [2 ,3 ,4 ]
Engelborghs, Sebastiaan [3 ,5 ]
Pickut, Barbara [6 ]
de Pooter, Tim [1 ,2 ,3 ]
Peeters, Karin [1 ,2 ,3 ]
Mattheijssens, Maria [1 ,2 ,3 ]
Van den Broeck, Marleen [1 ,2 ,3 ]
Cras, Patrick [3 ,4 ]
De Deyn, Peter Paul [3 ,5 ,6 ]
van Broeckhoven, Christine [1 ,2 ,3 ]
机构
[1] Univ Antwer, Neurodegenerat Brain Dis Grp, Dept Mol Genet, CDE,VIB, B-2610 Antwerp, Belgium
[2] Inst Born Bunge, Neurogenet Lab, Antwerp, Belgium
[3] Univ Antwerp, Born Bunge Fdn, Neurobiol Lab, B-2020 Antwerp, Belgium
[4] Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium
[5] Inst Born Bunge, Lab Neurochem & Behav, Antwerp, Belgium
[6] ZNA Middleheim Gen Hosp, Div Neurol, Antwerp, Belgium
关键词
Parkinson's disease; LRRK2; p.R1441C founder mutation;
D O I
10.1038/sj.ejhg.5201986
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We determined the prevalence of mutations in two major functional domains of the leucine-rich repeat kinase 2 gene (LRRK2) in Belgian Parkinson's disease (PD) patients (N = 304) of which 18.1% were familial PD patients. Ten patients were heterozygous for five different missense mutations (3.29%) of whom six carried the same mutation p. R1441C (1.97%). All six p. R1441C carriers were familial PD patients explaining 10.7% of familial PD in the Belgian patient group. Moreover, they shared a common disease haplotype of 21 consecutive markers in a region of 438 kb, suggesting that they are distant descendants of a single common ancestor. Clinically, p. R1441C carriers had typical levodopa-responsive parkinsonism with tremor as the most common presenting feature. Their age at onset was highly variable and ranged from 39 to 73 years, suggesting the influence of modifying factors. The remaining four patients were heterozygous each for a novel missense mutation located in the Roc or kinase domain. The pathogenic nature of these mutations remains to be determined, though we have genetic evidence that at least some represent rare but benign variants rather than causal mutations. The latter observation indicates that prudence is needed in diagnostic testing of LRRK2 in PD patients. Functional data should underlie a conclusion on the pathogenic nature of some mutations that have not been conclusively linked to disease.
引用
收藏
页码:471 / 479
页数:9
相关论文
共 50 条
  • [41] Leucine-rich repeat kinase 2: A new player with a familiar theme for Parkinson's disease pathogenesis
    Li, CJ
    Beal, MF
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (46) : 16535 - 16536
  • [42] Leucine-Rich Repeat Kinase 2-Linked Parkinson's Disease: Clinical and Molecular Findings
    Kumari, Udhaya
    Tan, Eng-King
    JOURNAL OF MOVEMENT DISORDERS, 2010, 3 (02) : 25 - 31
  • [43] Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
    Lee, Byoung Dae
    Shin, Joo-Ho
    VanKampen, Jackalina
    Petrucelli, Leonard
    West, Andrew B.
    Ko, Han Seok
    Lee, Yun-Il
    Maguire-Zeiss, Kathleen A.
    Bowers, William J.
    Federoff, Howard J.
    Dawson, Valina L.
    Dawson, Ted M.
    NATURE MEDICINE, 2010, 16 (09) : 998 - 1000
  • [44] Can Leucine-Rich Repeat Kinase 2 Inhibition Benefit GBA-Parkinson's Disease?
    Bonet-Ponce, Luis
    Cookson, Mark R.
    MOVEMENT DISORDERS, 2020, 35 (05) : 721 - 723
  • [45] Absence of Commonly Reported Leucine-Rich Repeat Kinase 2 Mutations in Eastern Indian Parkinson's Disease Patients
    Sanyal, Jaya
    Sarkar, Biswanath
    Ojha, Sabyasachi
    Banerjee, Tapas Kumar
    Ray, Bidhan Chandra
    Rao, Vadlam Raghavendra
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2010, 14 (05) : 691 - 694
  • [46] Mood and Cognition in Leucine-Rich Repeat Kinase 2 G2019S Parkinson's Disease
    Shanker, Vicki
    Groves, Mark
    Heiman, Gary
    Palmese, Christina
    Saunders-Pullman, Rachel
    Ozelius, Laurie
    Raymond, Deborah
    Bressman, Susan
    MOVEMENT DISORDERS, 2011, 26 (10) : 1875 - 1880
  • [47] Leucine-Rich Repeat Kinase 2 (LRRK2): A Key Player in the Pathogenesis of Parkinson's Disease
    Gandhi, Payal N.
    Chen, Shu G.
    Wilson-Delfosse, Amy L.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2009, 87 (06) : 1283 - 1295
  • [48] Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease
    Lee, Byoung Dae
    Dawson, Valina L.
    Dawson, Ted M.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (07) : 365 - 373
  • [49] Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease
    Bardien, Soraya
    Lesage, Suzanne
    Brice, Alexis
    Carr, Jonathan
    PARKINSONISM & RELATED DISORDERS, 2011, 17 (07) : 501 - 508
  • [50] Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond
    Bae, Jae Ryul
    Lee, Byoung Dae
    BMB REPORTS, 2015, 48 (05) : 243 - 248